NewGen Secures $19 Million Valuation for UAE Cytometry Unit as IVF Market Booms
NIVF•NewGen’s UAE-based cell sorting and cytometry leasing entity received a US$19 million Big Four valuation, up from US$17.9 million in October 2025. The company will lease cytometry devices to UAE clinics, targeting an IVF market forecast to expand from US$270 million in 2024 to US$444 million by 2030.
1. Big Four Valuation for Planned UAE Entity
NewGen secured an independent midpoint equity valuation of US$19 million for its planned UAE cell sorting and cytometry leasing entity as of May 31, 2026. This follows a US$17.9 million valuation of its cytometry intellectual property in October 2025, underscoring growing investor confidence in its platform.
2. GCC IVF Market Opportunity
The UAE IVF market is projected to grow from US$270 million in 2024 to US$444 million by 2030 at a CAGR of approximately 8.5%, driven by high regional infertility rates and medical tourism inflows from China and India. NewGen’s entry into this high-growth segment aims to capture both domestic demand and cross-border patient volumes.
3. Cytometry Leasing Business Model
NewGen will lease advanced cytometry devices to local clinics on a fixed lease plus variable consumables basis, while operating a centralized, high-throughput cell sorting hub in the UAE. This asset-light approach leverages synergies with NewGen’s Ras Al Khaimah real estate developments to create an integrated medical tourism ecosystem.
4. Strategic Advisor Appointment
Industry veteran Nadeem Malik has been appointed Senior Strategic Advisor to spearhead the UAE and broader GCC rollout. Malik’s track record includes leadership roles at Genetics and IVF Institute and Fairfax Cryobank, positioning him to accelerate commercialization and scale NewGen’s cytometry platform.
